The Relationship Between Anxiety and Time to Treatment for Patients With Prostate Cancer on Surveillance

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 826-832

  Latini, David M ^a   Hart, Stacey L ^b   Knight, Sara J ^b,c   Cowan, Janet E ^b,c   Ross, Phillip L ^b,c   DuChane, Janeen ^d   Carroll, Peter R ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

anxiety; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANXIETY; ARTICLE; CANCER REGISTRY; DEMOGRAPHY; EDUCATION; ETHNICITY; GLEASON SCORE; HUMAN; INCOME; INSURANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSOCIAL CARE; QUALITY OF LIFE; STATISTICAL ANALYSIS;

AGED; ANXIETY; DECISION MAKING; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 34547818148     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.039     Document Type: Article

References (20)

1. Scherr D., Swindle P.W., and Scardino P.T. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61 (2003) 14
2. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141
3. Meng M.V., Elkin E.P., Harlan S.R., Mehta S.S., Lubeck D.P., and Carroll P.R. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 170 (2003) 2279
4. Zietman A.L., Thakral H., Wilson L., and Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 166 (2001) 1702
5. Cancer Facts and Figures 2006 (2006), American Cancer Society, Atlanta
6. Potosky A.L., Davis W.W., Hoffman R.M., Stanford J.L., Stephenson R.A., Penson D.F., et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96 (2004) 1358
7. Murphy A.M., McKiernan J.M., and Olsson C.A. Controversies in prostate cancer screening. J Urol 172 (2004) 1822
8. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
9. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 30 (2003) 303
10. Dale W., Bilir P., Han M., and Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 104 (2005) 467
11. Patel M.I., DeConcini D.T., Lopez-Corona E., Ohori M., Wheeler T., and Scardino P.T. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171 (2004) 1520
12. Lubeck D.P., Litwin M.S., Henning J.M., Stier D.M., Mazonson P., Fisk R., et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48 (1996) 773
13. Hill J.M., Kornblith A.B., Jones D., Freeman A., Holland J.F., Glicksman A.S., et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 82 (1998) 208
14. Greenberg D.B., Kornblith A.B., Herndon J.E., Zuckerman E., Schiffer C.A., Weiss R.B., et al. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer 80 (1997) 1936
15. Mehta S.S., Lubeck D.P., Pasta D.J., and Litwin M.S. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 170 (2003) 1931
16. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293
17. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
18. Cooperberg M.R., Pasta D.J., Elkin E.P., Litwin M.S., Latini D.M., DuChane J., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (2005) 1938
19. Bailey D.E., Mishel M.H., Belyea M., Stewart J.L., and Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 27 (2004) 339
20. Roth A.J., Rosenfeld B., Kornblith A.B., Gibson C., Scher H.I., Curley-Smart T., et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97 (2003) 2910